StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEKFree Report) in a research report released on Monday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Down 0.9 %

Shares of CHEK opened at $0.80 on Monday. Check-Cap has a 52-week low of $0.76 and a 52-week high of $3.45. The stock has a fifty day simple moving average of $1.19 and a two-hundred day simple moving average of $1.73. The company has a market capitalization of $4.68 million, a PE ratio of -0.27 and a beta of 0.39.

Check-Cap Company Profile

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Featured Articles

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.